How is MONJUVI unique?
MONJUVI is not chemotherapy, which makes it different from some of the other DLBCL treatments you may have taken or read about.
MONJUVI is targeted immunotherapy, which means it helps the immune system find and kill cancerous cells. Because of the way MONJUVI works with your immune system, treatment is given on a long-term basis to help you achieve and maintain control of your disease.
“It’s fascinating that you can take something that makes your own cells fight the cancer.”
—Gloria, living with DLBCL
How does MONJUVI work?
B cells are part of a person’s immune system. They help your body fight infection. In DLBCL, B cells grow out of control, both in size and number. MONJUVI targets cancerous B cells directly and activates your immune system to fight relapsed or refractory DLBCL. MONJUVI can also affect healthy cells. The images below show how MONJUVI works.
1
Cancerous B cell with CD19 markers.
2
MONJUVI locates and binds
to the CD19 marker on the surface
of cancerous B cells.
3
This binding action triggers
immune cells to kill the cancer cells.
Long-term clinical study results with MONJUVI
A chance to reach and maintain remission with MONJUVI
The combination of MONJUVI and lenalidomide was studied in 71 people whose DLBCL came back, got worse, or didn’t respond to treatment and who could not receive a stem cell transplant. They received this treatment for up to 12 cycles. Then, they were given MONJUVI alone.
People in this study had several follow-up visits with their doctor to see how their treatment was going. Results from these visits were measured at 2 points in time: 1 year and 5 years after the last patient started treatment.
How many people reached remission with MONJUVI?
*Complete remission: the disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured.
†Partial remission: a decrease (usually at least 50% in DLBCL) in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
How your condition progresses and how you may respond to MONJUVI depends on your individual circumstances.
In the 5-year analysis, a similar number of people who received MONJUVI and lenalidomide reached either complete or partial remission.
For people in the study who reached remission, how long did remission last?
MONJUVI, in combination with lenalidomide, was approved by the US Food and Drug Administration (FDA) based on results from the 1-year analysis. The FDA has not reviewed results from the 5-year analysis, and these results are not included in the final FDA-approved Prescribing Information.
The 5-year analysis also looked at how long people who responded to treatment continued to stay in complete or partial remission. These results are based on 38 out of 71 people who responded during the 5-year analysis.
Talk to your doctor about MONJUVI
When it’s time for the next treatment step, asking the right questions is an important part of making the decision. The Doctor Discussion Guide helps you prepare for a conversation with your healthcare team.
Download GuideLearn more about how you will receive MONJUVI and your treatment schedule.